29. The pharmaceutical composition of any one of Claims 22 to 28, wherein the glidant is about 0.1 to 3 weight %.

30. The pharmaceutical composition of any one of Claims 22 to 29, wherein the lubricant is about 0.1 to 3 weight %.

31. A pharmaceutical composition comprising:

(a) *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; and

(b) sodium bicarbonate.

32. A pharmaceutical composition comprising:

(a) a solid dispersion of any one of Claims 1 to 19; and

(b) sodium bicarbonate.

33. A pharmaceutical composition comprising:

(a) about 1 to about 70 weight % of the solid dispersion of any one of Claims 1 to 15; and

(b) about 0.1 to about 30 weight % sodium bicarbonate.

34. The pharmaceutical composition of any one of Claims 31 to 33, wherein the remaining weight of the composition is other pharmaceutically acceptable excipients and carriers.

35. The pharmaceutical composition of any one of Claims 22 to 30 or 32 to 34, wherein the solid dispersion is about 25 to about 60 weight %.

36. The pharmaceutical composition of any one of Claims 22 to 30 or 32 to 35, wherein the solid dispersion is about 40 to about 60 weight %.

37. The pharmaceutical composition of any one of Claims 22 to 36, wherein the composition is a tablet.

38. A method for the treatment of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a solid dispersion or composition of any one of Claims 1 to 37.

39. The method of Claim 38, wherein the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian, uterine and brain cancer.

40. The method of Claims 38 or 39, wherein the cancer is ErbB2 positive.

41. Use of a pharmaceutical composition of any one of Claims 1 to 37 in the manufacture of a medicament for the treatment of cancer.

42. The use of Claim 41, wherein the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian, uterine and brain cancer.

43. The use of Claims 41 or 42, wherein the cancer is ErbB2 positive.

44. The solid dispersion of any one of Claims 1 to 19 for the treatment of disease.

45. The solid dispersion of Claim 44, wherein the disease is a hyperproliferative disease.

46. The solid dispersion of Claim 45, wherein the hyperproliferative disease is cancer.

47. The solid dispersion of Claim 46, wherein the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian, uterine and brain cancer.

48. The solid dispersion of Claims 46 or 47, wherein the cancer is ErbB2 positive.

49. The pharmaceutical composition of any one of Claims 20 to 37 for the treatment of disease.

50. The solid dispersion of Claim 49, wherein the disease is a hyperproliferative disease.

51. The solid dispersion of Claim 50, wherein the hyperproliferative disease is cancer.

52. The solid dispersion of Claim 51, wherein the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian, uterine and brain cancer.

53. The solid dispersion of Claims 50 or 51, wherein the cancer is ErbB2 positive.

54. A process of preparing a solid dispersion of any one of Claims 1 to 19 comprising the steps of:

(a) dissolving *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer in a suitable solvent; and

(b) evaporating the solvent to form the solid dispersion.

55. The process of Claim 54, wherein the evaporation of the solvent in step (b) is performed by spray drying, melt extrusion, freeze drying, rotary evaporation, drum drying or other solvent removal processes.

56. The process of Claims 54 or 55, comprising the steps of:

(a) dissolving *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer in a suitable solvent to form a feed solution; and

(b) spray drying the feed solution to form the solid dispersion.

57. A process for preparing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine comprising spray drying *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.

58. The process of Claim 57, wherein the spray drying also includes a dispersion polymer.

59. The process of Claims 57 or 58, wherein the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is dissolved in a suitable solvent.

29. The pharmaceutical composition of any one of Claims 22 to 28, wherein the glidant is about 0.1 to 3 weight %.

30. The pharmaceutical composition of any one of Claims 22 to 29, wherein the lubricant is about 0.1 to 3 weight %.

31. A pharmaceutical composition comprising:

(a) *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; and

(b) sodium bicarbonate.

32. A pharmaceutical composition comprising:

(a) a solid dispersion of any one of Claims 1 to 19; and

(b) sodium bicarbonate.

33. A pharmaceutical composition comprising:

(a) about 1 to about 70 weight % of the solid dispersion of any one of Claims 1 to 15; and

(b) about 0.1 to about 30 weight % sodium bicarbonate.

34. The pharmaceutical composition of any one of Claims 31 to 33, wherein the remaining weight of the composition is other pharmaceutically acceptable excipients and carriers.

35. The pharmaceutical composition of any one of Claims 22 to 30 or 32 to 34, wherein the solid dispersion is about 25 to about 60 weight %.

36. The pharmaceutical composition of any one of Claims 22 to 30 or 32 to 35, wherein the solid dispersion is about 40 to about 60 weight %.

37. The pharmaceutical composition of any one of Claims 22 to 36, wherein the composition is a tablet.

38. Use of a pharmaceutical composition of any one of Claims 1 to 37 in the manufacture of a medicament for the treatment of cancer.

39. The use of Claim 38, wherein the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian, uterine and brain cancer.

40. The use of Claims 38 or 39, wherein the cancer is ErbB2 positive.

41. The solid dispersion of any one of Claims 1 to 19 for the treatment of disease.

42. The solid dispersion of Claim 41, wherein the disease is a hyperproliferative disease.

43. The solid dispersion of Claim 42, wherein the hyperproliferative disease is cancer.

44. The solid dispersion of Claim 43, wherein the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian, uterine and brain cancer.

45. The solid dispersion of Claims 43 or 44, wherein the cancer is ErbB2 positive.

46. The pharmaceutical composition of any one of Claims 20 to 37 for the treatment of disease.

47. The solid dispersion of the pharmaceutical composition of Claim 46, wherein the disease is a hyperproliferative disease.

48. The solid dispersion of the pharmaceutical composition of Claim 47, wherein the hyperproliferative disease is cancer.

49. The solid dispersion of the pharmaceutical composition of Claim 48, wherein the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian, uterine and brain cancer.

50. The solid dispersion of the pharmaceutical composition of Claims 47 or 48, wherein the cancer is ErbB2 positive.

51. A process of preparing a solid dispersion of any one of Claims 1 to 19 comprising the steps of:

(a) dissolving *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer in a suitable solvent; and

(b) evaporating the solvent to form the solid dispersion.

52. The process of Claim 51, wherein the evaporation of the solvent in step (b) is performed by spray drying, melt extrusion, freeze drying, rotary evaporation, drum drying or other solvent removal processes.

53. The process of Claims 51 or 52, comprising the steps of:

(a) dissolving *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer in a suitable solvent to form a feed solution; and

(b) spray drying the feed solution to form the solid dispersion.